COVID-19: Publikationen


Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients
Biomarkers of Pro-Inflammatory Response May Identifiy Cancer Patients at Risk of Adverse Outcomes From SARS-CoV-2 Infection
The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy
Radiation treatment of hemato-oncological patients in times of the COVID-19 pandemic : Expert recommendations from the radiation oncology panels of the German Hodgkin Study Group and the German Lymphoma Alliance
COVID-19 in cancer patients: clinical characteristics and outcome—an analysis of the LEOSS registry
When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities
The LNT Issue Is About Politics and Economics, Not Safety.
Caring for AML Patients During the COVID-19 Crisis: An American and Italian Experience.
Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study.
COVID-19 in cancer patients can be challenging to screen in a resource limited setting.
Cancer inpatients with COVID-19: A report from the Brazilian National Cancer Institute.
COVID-19 and myeloproliferative neoplasms: some considerations
Concurrent Diagnosis of Acute Myeloid Leukemia and COVID-19: A Management Challenge.
Successful management of SARS-CoV-2 acute respiratory distress syndrome and newly diagnosed acute lymphoblastic leukemia
Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study
The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
Guidelines for therapy of patients with chronic myeloproliferative neoplasms during the novel coronavirus SARS-CoV2 pandemic.
Evaluation of COVID 19 infection in 279 cancer patients treated during a 90-day period in 2020 pandemic.
Prevalence of COVID-19 diagnosis in Dutch CML patients during the 2020 SARS-CoV2 pandemic. A prospective cohort study.
How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy-a GIMEMA MPN WP survey.
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey.
Regional BCG vaccination policy in former East- and West Germany may impact on both severity of SARS-CoV-2 and incidence of childhood leukemia.
Risk factors for death in 1859 subjects with COVID-19.
Rewriting the rules for care of MDS and AML patients in the time of COVID-19
Optimal Management of Acute Lymphoblastic Leukemia (ALL) in Adult Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic
Frequently Asked Questions Regarding SARS-CoV-2 in Cancer Patients-Recommendations for Clinicians Caring for Patients With Malignant Diseases
Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation
Management of hematologic disease under the COVID-19 pandemic: experience from China
ILROG Emergency Guidelines for Radiation Therapy of Hematological Malignancies During the COVID-19 Pandemic
Treating Leukemia in the Time of COVID-19
Risk of COVID-19 for patients with cancer
Managing COVID-19 in the oncology clinic and avoiding the distraction effect
Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists’ perspective
Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic
Hematology in the time of COVID-19
Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic
Oncology Practice During the COVID-19 Pandemic
Acute leukemia in the time of COVID-19


Outcome of hospitalized patients with hematological malignancies and COVID-19 infection in a large urban healthcare trust in the United Kingdom
COVID-19 in Chronic-Phase Chronic Myeloid Leukemia Patients: A Single Center Survey from Turkey
Convalescent Plasma Rescued a Severe COVID-19 Patient with Chronic Myeloid Leukemia Blast Crisis and Myelofibrosis.
Treatment of Immunocompromised COVID-19 patients with Convalescent Plasma.
Fatal Invasive Pulmonary Aspergillosis in COVID-19 Patient with Acute Myeloid Leukemia in Iran.
Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia.
Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors.
COVID - 19 post Hematopoietic Cell Transplant, a Report of 11 Cases from a Single Center
COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
Clinical characteristics and outcome of SARS-CoV-2-infected patients with haematological diseases: a retrospective case study in four hospitals in Italy, Spain and the Netherlands.
Clinical characteristics of four cancer patients with SARS-CoV-2 infection in Wuhan, China.
Clinical Characteristics of Hematological Patients Concomitant with COVID-19.
Impact of Covid-19 on the treatment of acute myeloid leukemia.
Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).
Confirmed Coronavirus Disease-19 (COVID-19) in a Male with Chronic Myeloid Leukemia Complicated by Febrile Neutropenia and Acute Respiratory Distress Syndrome.
Atypical Imaging Findings in Leukemia With SARS-CoV-2 Infection
SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection
Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies
Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia
COVID-19 in persons with chronic myeloid leukaemia
COVID-19 in persons with haematological cancers
Response to "COVID-19 in persons with haematological cancers"
Reply to “COVID-19 in persons with haematological cancers”: a focus on myeloid neoplasms and risk factors for mortality

Behandlung und Mechanismus

Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19
Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
Imatinib is not a potent anti-SARS-CoV-2 drug.
Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2.
Detection of SARS-CoV-2 viremia before onset of COVID-19 symptoms in an allo-transplanted patient with acute leukemia.
Effect of hydroxychloroquine on COVID-19 prevention in cancer patients undergoing treatment: a structured summary of a study protocol for a randomised controlled trial.
Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation
Poor outcome in patients with acute leukemia on intensive chemotherapy and COVID-19
SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine "storm" and risk factor for damage of hematopoietic stem cells
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
Identification of potential inhibitors of SARS-COV-2 endoribonuclease (EndoU) from FDA approved drugs: a drug repurposing approach to find therapeutics for COVID-19
Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis
Cancer Patients in SARS-CoV-2 Infection: A Nationwide Analysis in China
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1
Hematological features of persons with COVID-19
Lower Antibodies Rate in Cancer Patients After Symptomatic COVID-19 Than In Healthcare Workers

Pädiatrische Patienten

Management of an Immunocompromised Pediatric Patient With Multiple Hospitalizations for Symptomatic COVID-19
SARS-CoV-2 convalescent plasma therapy in pediatric patient after hematopoietic stem cell transplantation
Acute lymphoblastic leukemia onset in a 3-year-old child with COVID-19.
Comment on: Acute lymphoblastic leukemia onset in a 3-year-old child with COVID-19.
Convalescent plasma to aid in recovery of COVID-19 pneumonia in a child with acute lymphoblastic leukemia.
A Child with Acute Lymphoblastic Leukemia in Institutional Isolation during the COVID Pandemic: A Multifaceted Responsibility.
SARS-CoV-2 viral clearance during bone marrow aplasia after allogeneic hematopoietic stem cell transplantation - a case report.
SARS-CoV-2 Infection During Induction Chemotherapy in a Child With High-risk T-Cell Acute Lymphoblastic Leukemia (T-ALL)
Clinical characteristics and outcome of SARS-CoV-2 infection in Italian pediatric oncology patients: a study from the Infectious Diseases Working Group of the AIEOP.
SARS-CoV-2 infection in a neutropenic pediatric patient with leukemia: Addressing the need for universal guidelines for treatment of SARS-CoV-2-positive, immunocompromised patients.
COVID-19 and childhood acute lymphoblastic leukemia
COVID-19 and acute lymphoblastic leukemias of children and adolescents: First recommendations of the Leukemia committee of the French Society for the fight against Cancers and Leukemias in children and adolescents (SFCE)
Clinical Strategies for Treating Pediatric Cancer During the Outbreak of 2019 Novel Coronavirus Infection
Challenges posed by COVID-19 to children with cancer